These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 18495158)

  • 21. The crystallographic structure of the aldose reductase-IDD552 complex shows direct proton donation from tyrosine 48.
    Ruiz F; Hazemann I; Mitschler A; Joachimiak A; Schneider T; Karplus M; Podjarny A
    Acta Crystallogr D Biol Crystallogr; 2004 Aug; 60(Pt 8):1347-54. PubMed ID: 15272156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FlexE: efficient molecular docking considering protein structure variations.
    Claussen H; Buning C; Rarey M; Lengauer T
    J Mol Biol; 2001 Apr; 308(2):377-95. PubMed ID: 11327774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme.
    El-Kabbani O; Ramsland P; Darmanin C; Chung RP; Podjarny A
    Proteins; 2003 Feb; 50(2):230-8. PubMed ID: 12486717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity.
    Barski OA; Gabbay KH; Bohren KM
    Biochemistry; 1996 Nov; 35(45):14276-80. PubMed ID: 8916913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
    Ruiz FX; Cousido-Siah A; Mitschler A; Farrés J; Parés X; Podjarny A
    Chem Biol Interact; 2013 Feb; 202(1-3):178-85. PubMed ID: 23295227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ultrahigh resolution drug design I: details of interactions in human aldose reductase-inhibitor complex at 0.66 A.
    Howard EI; Sanishvili R; Cachau RE; Mitschler A; Chevrier B; Barth P; Lamour V; Van Zandt M; Sibley E; Bon C; Moras D; Schneider TR; Joachimiak A; Podjarny A
    Proteins; 2004 Jun; 55(4):792-804. PubMed ID: 15146478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2.
    Kato A; Kobayashi K; Narukawa K; Minoshima Y; Adachi I; Hirono S; Nash RJ
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5630-3. PubMed ID: 20805028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of new selective human aldose reductase inhibitors through virtual screening multiple binding pocket conformations.
    Wang L; Gu Q; Zheng X; Ye J; Liu Z; Li J; Hu X; Hagler A; Xu J
    J Chem Inf Model; 2013 Sep; 53(9):2409-22. PubMed ID: 23901876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors.
    El-Kabbani O; Darmanin C; Schneider TR; Hazemann I; Ruiz F; Oka M; Joachimiak A; Schulze-Briese C; Tomizaki T; Mitschler A; Podjarny A
    Proteins; 2004 Jun; 55(4):805-13. PubMed ID: 15146479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ligand-induced fit affects binding modes and provokes changes in crystal packing of aldose reductase.
    Koch C; Heine A; Klebe G
    Biochim Biophys Acta; 2011 Sep; 1810(9):879-87. PubMed ID: 21684320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Probing the inhibitor-binding site of aldose reductase with site-directed mutagenesis.
    Hohman TC; El-Kabbani O; Malamas MS; Lai K; Putilina T; McGowan MH; Wane YQ; Carper DA
    Eur J Biochem; 1998 Sep; 256(2):310-6. PubMed ID: 9760169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expect the unexpected or caveat for drug designers: multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallisation conditions.
    Steuber H; Zentgraf M; Gerlach C; Sotriffer CA; Heine A; Klebe G
    J Mol Biol; 2006 Oct; 363(1):174-87. PubMed ID: 16952371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of aldose reductase inhibition and docking studies of some secondary metabolites, isolated from Origanum vulgare L. ssp. hirtum.
    Koukoulitsa C; Zika C; Geromichalos GD; Demopoulos VJ; Skaltsa H
    Bioorg Med Chem; 2006 Mar; 14(5):1653-9. PubMed ID: 16249088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors.
    Ferrari AM; Degliesposti G; Sgobba M; Rastelli G
    Bioorg Med Chem; 2007 Dec; 15(24):7865-77. PubMed ID: 17870536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of C7 modifications on benzothiadiazine-1,1-dioxide derivatives on their inhibitory activity and selectivity toward aldose reductase.
    Zhang S; Chen X; Parveen S; Hussain S; Yang Y; Jing C; Zhu C
    ChemMedChem; 2013 Apr; 8(4):603-13. PubMed ID: 23136050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virtual screening for inhibitors of human aldose reductase.
    Kraemer O; Hazemann I; Podjarny AD; Klebe G
    Proteins; 2004 Jun; 55(4):814-23. PubMed ID: 15146480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and synthesis of potent and selective aldose reductase inhibitors based on pyridylthiadiazine scaffold.
    Chen X; Yang Y; Ma B; Zhang S; He M; Gui D; Hussain S; Jing C; Zhu C; Yu Q; Liu Y
    Eur J Med Chem; 2011 May; 46(5):1536-44. PubMed ID: 21367494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites.
    El-Kabbani O; Podjarny A
    Cell Mol Life Sci; 2007 Aug; 64(15):1970-8. PubMed ID: 17497245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of inhibitor aliphatic chain in the thermodynamics of inhibitor binding to Escherichia coli enoyl-ACP reductase and the Phe203Leu mutant: a proposed mechanism for drug resistance.
    Protasevich II; Brouillette CG; Snow ME; Dunham S; Rubin JR; Gogliotti R; Siegel K
    Biochemistry; 2004 Oct; 43(42):13380-9. PubMed ID: 15491144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor Fidarestat: stereospecific interaction between the enzyme and a cyclic imide type inhibitor.
    El-Kabbani O; Darmanin C; Oka M; Schulze-Briese C; Tomizaki T; Hazemann I; Mitschler A; Podjarny A
    J Med Chem; 2004 Aug; 47(18):4530-7. PubMed ID: 15317464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.